|
A Multicenter, Randomized, Placebo Controlled Phase 2B Study Assessing the Safety and Efficacy of Early Administration of Intravenous CD-NP Versus Placebo in the Treatment of Patients with Acute Decompensated Heart Failure (ADHF) - Condition HF Trial (Protocol #09-24-H-05)
Would you like to participate in a new drug research study for Congestive Heart Failure?
We are currently recruiting patients who have been admitted in the hospital with a diagnosis of Congestive Heart Failure within the last 8 hours into a new drug research study. You may be a candidate for the trial if you...
• Have been admitted in the Mount Sinai Emergency Room in the past 24 hours with a diagnosis of
Congestive Heart Failure
• Are older than 18 years old
• Are not pregnant
• Are not participating in any other research studies
If you qualify to take part in this study, there will not be any additional cost to you. Please call 305-674-2162 to learn if you qualify to take part.
Apixaban for Prevention of Acute Ischemic Events - 2: A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary (Protocol #09-26-H-05)
We are currently recruiting patients who have suffered a heart attack or ischemic stroke within the last week to participate into an anticoagulant clinical research trial. You may be a candidate to take part in the study if you:
• Have experienced your symptoms within the last week or have had a history of Mycardial Infarction
for no more than five years
• Are older than 18 years old
• Have diabetes
• Are not pregnant, planning a pregnancy or breast feeding
• Are not participating in any other research studies
• Meet other qualifications
If you qualify to take part in this study, there will not be any additional cost to you. Please call 305-674-2162 to learn if you are eligible to take part in this study. Fax communications can be sent to 305-674-2169.
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (Protocol #9-11-H-02)
We are currently recruiting patients who have suffered a heart attack within the last week into a stem cell clinical research trial. You may be a candidate for the trial if you...
- Have experienced your first heart attack within the last week
- Are 21 to 85 years old
- Are not pregnant, planning a pregnancy or breast feeding
- Are not participating in any other research studies
- Are not allergic to MRI dye, pork or beef products
- Other criteria apply
If you qualify to take part in this study, there will not be any additional cost to you. Please call 305-674-2162 to learn if you might be eligible to take part in this study. Fax communications can be sent to 305-674-2169.
For more information about participating in this trial, please visit:www.Osiris.com
Trial to Assess Chelation Therapy - TACT (Protocol #09-06-H-01)
• Have you ever had a heart attack?
• Are you age 50 or older and non-smoker?
You or someone you know may be eligible to take part in a large international research study of an alternative treatment - chelation therapy and vitamin therapy. The Trial to Assess Chelation Therapy (TACT) is a randomized, double-blind, placebo controlled study that will determine whether or not chelation therapy is a safe and effective treatment for cardiovascular disease. If you qualify to take part in this study, there will not be any additional cost to you. Please call 305-674-2162 for more information.
SPIROCOR Coronary Outcome by Respiratory Stress Examination - SCORE Study
(Protocol #10-01-H-01)
We are currently recruiting patients into an investigational research study named SPIROCOR Coronary Outcome by Respiratory Stress Examination (SCORE Study) to evaluate for possible significant coronary artery disease (CAD). You may be a candidate for the trial if you...
- Suspect of significant coronary artery disease (S-CAD)
- Are 30 years or older
- Have no known history of myocardial infarction
- Are able to perform synchronized breathing exercises for 90 seconds
- Are not participating in any other research studies
- Other requirements apply
If you qualify to take part in this study, there will not be any additional cost to you. Please call 305-674-2162 to learn if you might be eligible to take part in this study. Fax communications can be sent to 305-674-2169.
For more information about participating in this study, please visit: http://www.spirocor.com.
|
